JHS Svendgaard Laboratories Q1 Results Revenue ₹24.48 Crores & Net Loss ₹0.63 Crores

JHS Svendgaard Laboratories Growth Comparison 

JHS Svendgaard Laboratories Q1 Results: JHS Svendgaard Laboratories reported a total revenue of ₹24.48 crores in the first quarter of 2024. This is a 13.02% increase from the last quarter and a 53.95% rise compared to the same quarter last year, showing strong revenue growth. Their selling, general, and administrative expenses were ₹2.52 crores, which is slightly lower than the previous quarter but higher compared to a year ago. The company spent ₹1.97 crores on depreciation and amortization, up from the previous quarter but significantly more than a year ago.

JHS Svendgaard Laboratories’s other operating expenses dropped to ₹5.66 crores, a big decrease from the last quarter and slightly higher than last year. Total operating expenses were ₹24.49 crores, lower than the previous quarter but still higher than a year ago. Despite the revenue increase, the company had almost no operating income, which was a huge improvement from a loss of ₹23.79 crores last quarter but still a loss.

JHS Svendgaard Laboratories’s net income before taxes was ₹0.20 crores, a significant improvement from a loss last quarter. However, net income was still negative at -₹0.63 crores, which was worse than both the previous quarter and a year ago. The diluted normalized earnings per share (EPS) was -₹0.08, showing a decrease from the previous quarter and the same quarter last year. Overall, while revenue grew, the company still faced challenges in profitability.

Quarterly - JHS Svendgaard Laboratories Q1 Results 2024

Here's a simplified breakdown of JHS Svendgaard Laboratories' Q1 results:

Source: Here 

For More Q1 Results check our Twitter Page

Visit our website for more Q1 results

JHS Svendgaard Laboratories Q1 Results

JHS Svendgaard Laboratories earned a total income of ₹2,480.39 million in the first quarter of 2024. This includes ₹2,448.39 million from their main operations and ₹32.00 million from other sources. This was an increase from ₹2,303.71 million in the previous quarter but slightly higher than the ₹1,630.99 million from the same quarter last year. Their expenses for this quarter were ₹2,460.38 million, which is higher compared to ₹2,285.42 million in the previous quarter and ₹1,947.28 million from the same quarter last year. These expenses include costs for materials, stock purchases, changes in inventory, employee salaries, finance costs, depreciation, and other expenses.

After subtracting these expenses from their total income, the company reported a small profit of ₹20.01 million before considering any exceptional items or taxes. However, after taxes and other deductions, they ended up with a net loss of ₹62.80 million for the quarter. The company also reported a slight gain in other comprehensive income, resulting in a total comprehensive loss of ₹61.64 million for the period. Earnings per share were negative, showing a loss of ₹0.08 for both basic and diluted shares.

Here's the financial summary for the specified periods:

JHS Svendgaard Laboratories Financial Metrics 

JHS Svendgaard Laboratories is a company with a market capitalization of ₹205 Crore, meaning that's the total value of all its shares combined. The current stock price is ₹26.20, which is the price you would pay to buy one share. The stock has fluctuated between a high of ₹39.50 and a low of ₹15.50 in recent times. Its book value, which reflects the value of the company's assets minus liabilities, is ₹21.70. 

Here’s the financial data in table format:

Quarterly Results

JHS Svendgaard Laboratories' financial data for December 2023, March 2024, and June 2024 shows a mixed performance. In December 2023, the company had sales of ₹14.30 crores and expenses of ₹14.36 crores, leading to a small operating loss. However, by March 2024, sales increased to ₹21.66 crores, and expenses rose to ₹20.82 crores, resulting in a profit from operations. 

Here's the financial data for December 2023, March 2024, and June 2024:

About JHS Svendgaard Laboratories

JHS Svendgaard Laboratories began as a small business in August 1997, initially focusing on manufacturing toothbrushes. By October 8, 2004, it officially became JHS Svendgaard Laboratories, and just a few months later, in April 2005, the company expanded by taking over several businesses. It went public on October 21, 2006, and its shares were listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) of India.

JHS Svendgaard Laboratories quickly grew beyond toothbrushes to include products like toothpastes, mouthwashes, and denture tablets. JHS Svendgaard not only develops its own brands but also partners with other brands for contract manufacturing, both in India and abroad. One of its key brands is Dr. Gold, which offers a range of toothbrushes. The company has worked with well-known brands such as P&G and Amway and has international clients like Walgreens and Walmart.

JHS operates a fully automatic production facility in Kala Amb, Himachal Pradesh, which started in April 2007. The plant maintains high hygiene standards and has a team of skilled professionals to ensure smooth operations. The company is known for its quality products, using top materials and equipment from around the world, and it focuses on continuous innovation and quality control.